MedTrace Logo

A Herbal Compound for Psoriasis

NCT06301997 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2025-03-12

No results posted yet for this study

Summary

The goal of this interventional clinical trial study is to compare ZAX.1400.P03 and placebo in Psoriasis patients. The main question it aims to answer is:

• Can treatment with ZAX.1400.P03 for 3 weeks improve clinical signs of skin in psoriasis patients? Participants will be divided into two groups of 52 people. One group will use ZAX.1400.P03 topically twice daily for 3 weeks and the other group will use placebo topically twice daily for 3 weeks.

Researchers will compare treatment and placebo groups to see if there is any improvement in the clinical signs of skin caused by psoriasis after treatment with ZAX.1400.P03 for 3 weeks.

Conditions

Interventions

DIETARY_SUPPLEMENT

ZAX.1400.P03

ZAX.1400.P03, applied twice daily for 3 weeks after enrolment

DRUG

Placebo

Placebo, applied twice daily for 3 weeks after enrolment

Sponsors & Collaborators

  • Zarrin Avaye Kowsar Salamat (ZAX company) and HerbmedX

    collaborator UNKNOWN

  • Herbmedx Co

    collaborator INDUSTRY

  • Fasa University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-06-30
Completion
2025-07-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301997 on ClinicalTrials.gov